3.1.2. Comparing the Level of mROS in HSVSMCs from Non-Diabetic and T2DM Patients at Basal and After Treatment with IL-6/sIL-6Rα +/− Ruxolitinib and PDGF +/− Ruxolitinib. This evidence concerns the gene IL6 and type 2 diabetes mellitus.